Skip Navigation
Skip to contents

Intest Res : Intestinal Research

IMPACT FACTOR

Previous issues

Page Path
HOME > Browse articles > Previous issues
14 Previous issues
Filter
Filter
Article category
Keywords
Authors
Funded articles
Volume 20(3); July 2022
Prev issue Next issue
Editorial
IBD
Prevention of postoperative recurrence in Crohn’s disease: the never-ending story
Jung-Bin Park, Sang Hyoung Park
Intest Res 2022;20(3):279-280.   Published online July 26, 2022
DOI: https://doi.org/10.5217/ir.2022.00081
PDFPubReaderePub
  • 2,827 View
  • 161 Download
  • 1 Web of Science
Close layer
Reviews
Cancer
Endoscopic diagnosis and treatment of early colorectal cancer
Seung Wook Hong, Jeong-Sik Byeon
Intest Res 2022;20(3):281-290.   Published online July 26, 2022
DOI: https://doi.org/10.5217/ir.2021.00169
AbstractAbstract PDFPubReaderePub
Early colorectal cancer refers to cancer in the colorectum that is confined to the mucosa or submucosa and does not invade the muscularis propria, irrespective of lymph node or distant metastasis. As the number of persons undergoing screening colonoscopy increases, the proportion of patients diagnosed with precancerous colorectal lesions and early colorectal cancer also increases. In the last decade, innovative optical technologies for endoscopic diagnosis have been introduced and endoscopic treatment techniques such as endoscopic submucosal dissection have provided major breakthroughs in the management of early colorectal cancer. With these remarkable developments, endoscopic treatment has established itself as an alternative to surgical resection in the treatment of early colorectal cancer. This review will discuss the endoscopic diagnosis and treatment of early colorectal cancer. Furthermore, the unmet needs in this field and the latest research addressing those issues will be summarized.

Citations

Citations to this article as recorded by  
  • Artificial Intelligence Models May Aid in Predicting Lymph Node Metastasis in Patients with T1 Colorectal Cancer
    Ji Eun Baek, Hahn Yi, Seung Wook Hong, Subin Song, Ji Young Lee, Sung Wook Hwang, Sang Hyoung Park, Dong-Hoon Yang, Byong Duk Ye, Seung-Jae Myung, Suk-Kyun Yang, Namkug Kim, Jeong-Sik Byeon
    Gut and Liver.2025; 19(1): 69.     CrossRef
  • Case report: Successful treatment of advanced colon cancer in an eighty-year-old man with long-term and multi-stage endoscopic minimally invasive therapy
    Nana Zhang, Lulu Zhu, Yan Liu, Xiaolong Chen, Bifang Zhang, Chunhong Wen, Huayu Zhang, Qinglin Tang, Mingqing Zhang
    Frontiers in Oncology.2024;[Epub]     CrossRef
  • Prediction of Lymph Node Metastasis in T1 Colorectal Cancer Using Artificial Intelligence with Hematoxylin and Eosin-Stained Whole-Slide-Images of Endoscopic and Surgical Resection Specimens
    Joo Hye Song, Eun Ran Kim, Yiyu Hong, Insuk Sohn, Soomin Ahn, Seok-Hyung Kim, Kee-Taek Jang
    Cancers.2024; 16(10): 1900.     CrossRef
  • Influence of Certification Program on Treatment Quality and Survival for Rectal Cancer Patients in Germany: Results of 13 Certified Centers in Collaboration with AN Institute
    Mihailo Andric, Jessica Stockheim, Mirhasan Rahimli, Sara Al-Madhi, Sara Acciuffi, Maximilian Dölling, Roland Siegfried Croner, Aristotelis Perrakis
    Cancers.2024; 16(8): 1496.     CrossRef
  • Screening and surveillance for hereditary colorectal cancer
    Hee Man Kim, Tae Il Kim
    Intestinal Research.2024; 22(2): 119.     CrossRef
  • The Usefulness of Vitamin K-Dependent Proteins in the Diagnosis of Colorectal Carcinoma
    Mirela-Georgiana Perné, Adela-Viviana Sitar-Tăut, Olga Hilda Orășan, Vasile Negrean, Călin Vasile Vlad, Teodora-Gabriela Alexescu, Mircea Vasile Milaciu, Lorena Ciumărnean, Răzvan Dan Togănel, Gabriel Emil Petre, Ioan Șimon, Alexandra Crăciun
    International Journal of Molecular Sciences.2024; 25(9): 4997.     CrossRef
  • Strategies to improve screening colonoscopy quality for the prevention of colorectal cancer
    Joo Hye Song, Eun Ran Kim
    The Korean Journal of Internal Medicine.2024; 39(4): 547.     CrossRef
  • Patient and procedural factors associated with true histology rates in patients undergoing colonoscopy with computer-aided detection of polyps
    Aasma Shaukat, David R. Lichtenstein, Daniel C. Chung, Caitlyn Seidl, Yeli Wang, Emma E. Navajas, Daniel R. Colucci, Shrujal Baxi, William R. Brugge
    Gastrointestinal Endoscopy.2024; 100(6): 1090.     CrossRef
  • Short‐term morbidity and mortality after right hemicolectomy: an update of national performance in the Netherlands
    J. M. L. Sijmons, A. A. J. Grüter, B. R. Toorenvliet, R. A. E. M. Tollenaar, J. W. T. Dekker, P. J. Tanis, J. B. Tuynman
    Colorectal Disease.2024; 26(11): 1983.     CrossRef
  • Efficacy of Oral Sulfate Tablet and 2 L-Polyethylene Glycol With Ascorbic Acid for Bowel Preparation: A Prospective Randomized KASID Multicenter Trial
    Yunho Jung, Hyun Gun Kim, Dong-Hoon Yang, Hyoun Woo Kang, Jae Jun Park, Dong Hoon Baek, Jaeyoung Chun, Tae-Geun Gweon, Hyeon Jeong Goong, Min Seob Kwak, Hyun Jung Lee, Soo-Kyung Park, Jong Hoon Lee
    Journal of Korean Medical Science.2024;[Epub]     CrossRef
  • Olfactomedin 4 produces dysplasia but suppresses metastasis of colon cancer
    Hyun Woo Ma, Jung Min Kim, Da Hye Kim, I Seul Park, Ji Hyung Kim, Ki Cheong Park, Dong Hyuk Seo, Jae Hyeon Kim, Xiumei Che, Tae Il Kim, Jae Hee Cheon, Seung Won Kim
    Cancer Gene Therapy.2023; 30(5): 694.     CrossRef
  • Past, present, and future of Intestinal Research
    Jae Hee Cheon
    Intestinal Research.2023; 21(1): 1.     CrossRef
  • Chasm between Public Perceptions and Epidemiological Data on Colorectal Cancer
    Su Bee Park, Min Seob Kwak, Jin Young Yoon, Jae Myung Cha
    Gut and Liver.2023; 17(3): 449.     CrossRef
  • Technique, sedation, and clinical outcome of endoscopic submucosal dissection for rectal tumor with involvement of dentate line: A retrospective cohort study
    Yoon Kyoo Noh, Jun Lee, Seong Jung Kim
    Saudi Journal of Gastroenterology.2023; 29(6): 365.     CrossRef
  • Նորագույն էնդոսկոպիկ մեթոդների դերը հաստ աղու նորագոյացությունների ախտորոշման և բուժման մեջ
    Ն. Գ. Զալինյան, Ա. Մ. Խալաթյան, Ս. Ա. Խաչատրյան, Մ. Ա. Նալբանդյան, Տ. Է. Ստեփանյան, Գ. Ն. Թամամյան, Կ. Դ. Մանուկյան
    Medical Science of Armenia.2023; : 11.     CrossRef
  • Effectiveness and Safety of Endoscopic Submucosal Dissection for Colorectal Neoplasm in Patients with High Charlson Comorbidity Index Score: A HASID Multicenter Study
    Dong-Hyun Kim, Yong-Wook Jung, Byung-Chul Jin, Hyung-Hoon Oh, Hyo-Yeop Song, Seong-Jung Kim, Dae-Seong Myung, Sang-Wook Kim, Jun Lee, Geom-Seog Seo, Young-Eun Joo, Hyun-Soo Kim
    Journal of Clinical Medicine.2023; 12(19): 6255.     CrossRef
  • The tumor suppressive effect and apoptotic mechanism of TRAIL gene‐containing recombinant NDV in TRAIL‐resistant colorectal cancer HT‐29 cells and TRAIL‐nonresistant HCT116 cells, with each cell bearing a mouse model
    Bo‐Kyoung Jung, Yong Hee An, Sung Hoon Jang, Gyoungah Ryu, Saet‐byel Jung, Seonhee Kim, Cuk‐Seong Kim, Hyun Jang
    Cancer Medicine.2023; 12(20): 20380.     CrossRef
  • Clinical characteristics and risk factors related to polyposis recurrence and advanced neoplasm development among patients with non-hereditary colorectal polyposis
    Jihun Jang, Jihye Park, Soo Jung Park, Jae Jun Park, Jae Hee Cheon, Tae Il Kim
    Intestinal Research.2023; 21(4): 510.     CrossRef
  • Summary and comparison of recently updated post-polypectomy surveillance guidelines
    Yoon Suk Jung
    Intestinal Research.2023; 21(4): 443.     CrossRef
  • Wide-field endoscope accessory for multiplexed fluorescence imaging
    Gaoming Li, Miki Lee, Tse-Shao Chang, Joonyoung Yu, Haijun Li, Xiyu Duan, Xiaoli Wu, Sangeeta Jaiswal, Shuo Feng, Kenn R. Oldham, Thomas D. Wang
    Scientific Reports.2023;[Epub]     CrossRef
  • Endoscopic characterization of neoplastic and non-neoplastic lesions in inflammatory bowel disease: systematic review in the era of advanced endoscopic imaging
    Andrea Cassinotti, Marco Parravicini, Thomas P. Chapman, Marco Balzarini, Lorenzo Canova, Simone Segato, Valentina Zadro, Simon Travis, Sergio Segato
    Therapeutic Advances in Gastroenterology.2023;[Epub]     CrossRef
  • Prediction of disease recurrence or residual disease after primary endoscopic resection of pT1 colorectal cancer—results from a large nationwide Danish study
    Ilze Ose, Katarina Levic, Lau Caspar Thygesen, Orhan Bulut, Thue Bisgaard, Ismail Gögenur, Tine Plato Kuhlmann
    International Journal of Colorectal Disease.2023;[Epub]     CrossRef
  • 5,292 View
  • 286 Download
  • 20 Web of Science
  • 22 Crossref
Close layer
IBD
Landscape of inflammatory bowel disease in Singapore
Daren Low, Nidhi Swarup, Toshiyuki Okada, Emiko Mizoguchi
Intest Res 2022;20(3):291-296.   Published online January 7, 2022
DOI: https://doi.org/10.5217/ir.2021.00089
AbstractAbstract PDFPubReaderePub
Inflammatory bowel disease (IBD), primarily Crohn’s disease and ulcerative colitis, had been widely recognized to affect the Western population. However, the notable rise in prevalence of IBD in Asia, including Singapore, had garnered much attention to the causal role of the shift in trend, and more importantly, effective and safe management of the conditions of these groups of patients in terms of therapy, healthcare economics as well as patient well-being. This review presents a summary of the current landscape of IBD in Singapore, and discuss on areas that can be explored to improve and better understand the local condition, as prevalence continues to grow.

Citations

Citations to this article as recorded by  
  • Optimizing 5-aminosalicylate for moderate ulcerative colitis: expert recommendations from the Asia-Pacific, Middle East, and Africa Inflammatory Bowel Disease Coalition
    Filiz Akyüz, Yoon Kyo An, Jakob Begun, Satimai Aniwan, Huu Hoang Bui, Webber Chan, Chang Hwan Choi, Nazeer Chopdat, Susan J Connor, Devendra Desai, Emma Flanagan, Taku Kobayashi, Allen Yu-Hung Lai, Rupert W Leong, Alex Hwong-Ruey Leow, Wai Keung Leung, Ju
    Intestinal Research.2025; 23(1): 37.     CrossRef
  • Ocular extraintestinal manifestations and treatments in patients with inflammatory bowel disease
    Mariana Rodriguez Duran, Ghazala A. Datoo O’Keefe
    Frontiers in Ophthalmology.2024;[Epub]     CrossRef
  • Association of immune-mediated inflammatory diseases with depression and anxiety in patients with type 2 diabetes: A nationwide population-based study
    Oh Chan Kwon, Yuna Kim, Jaeyoung Chun, Kyungdo Han, Min-Chan Park, Ryul Kim, Jie-Hyun Kim, Young Hoon Youn, Hyojin Park
    Frontiers in Medicine.2023;[Epub]     CrossRef
  • Treatment of primary sclerosing cholangitis combined with inflammatory bowel disease
    You Sun Kim, Edward H. Hurley, Yoojeong Park, Sungjin Ko
    Intestinal Research.2023; 21(4): 420.     CrossRef
  • Evolving Trends and Burden of Inflammatory Bowel Disease in Asia, 1990–2019: A Comprehensive Analysis Based on the Global Burden of Disease Study
    Xuejie Chen, Xin Xiang, Weitong Xia, Xindi Li, Sidan Wang, Shuyu Ye, Li Tian, Lian Zhao, Feiyan Ai, Zhaohua Shen, Kai Nie, Minzi Deng, Xiaoyan Wang
    Journal of Epidemiology and Global Health.2023; 13(4): 725.     CrossRef
  • Is primary sclerosing cholangitis with inflammatory bowel disease different between patients in the East and West?
    Yong Eun Park
    Intestinal Research.2022; 20(2): 157.     CrossRef
  • Vaccination strategies for Korean patients with inflammatory bowel disease
    Yoo Jin Lee, Eun Soo Kim
    The Korean Journal of Internal Medicine.2022; 37(5): 920.     CrossRef
  • Clinical Characteristics of Korean Patients with Elderly-Onset Crohn’s Disease: Results from the Prospective CONNECT Study
    You Sun Kim, Min Jeong Na, Byong Duk Ye, Jae Hee Cheon, Jong Pil Im, Joo Sung Kim
    Gut and Liver.2022; 16(6): 995.     CrossRef
  • 6,561 View
  • 428 Download
  • 7 Web of Science
  • 8 Crossref
Close layer
Perspective
IBD
Endoscopy for assessment of mucosal healing in ulcerative colitis: time bound or response guided?
Ajit Sood, Ramit Mahajan, Arshdeep Singh, Vandana Midha, Varun Mehta
Intest Res 2022;20(3):297-302.   Published online February 8, 2022
DOI: https://doi.org/10.5217/ir.2021.00099
AbstractAbstract PDFPubReaderePub
The timing of colonoscopy in patients with active ulcerative colitis (UC) lacks coherence. The published guidelines and recommendations advocate time-bound colonoscopy in patients with active UC to assess for mucosal healing. However, the practice of performing colonoscopies at fixed time frames lacks reasoning. The time to achieve mucosal healing in UC is not uniform across the patient populations and is influenced by the disease severity and efficacy and time to therapeutic response of the drugs being used. Additionally, with the availability of sensitive noninvasive inflammatory biomarkers such as fecal calprotectin, that parallel the disease activity and correlate with mucosal healing, the notion of performing colonoscopy at fixed intervals sounds unjustifiable. The authors express their view that a response-guided colonoscopy (driven by normalization of clinical symptoms and inflammatory biomarkers), rather than a time-bound colonoscopy, would be more logical, apart from being cost-effective and patient-friendly.

Citations

Citations to this article as recorded by  
  • Comments on Oral Sulfate Solution Is as Effective as Polyethylene Glycol with Ascorbic Acid in a Split Method for Bowel Preparation in Patients with Inactive Ulcerative Colitis: A Randomized, Multicenter, and Single-Blind Clinical Trial
    Ji Eun Kim
    Gut and Liver.2024; 18(1): 192.     CrossRef
  • Ischemia-modified albumin: a novel blood marker of endoscopic mucosal healing in inflammatory bowel disease
    Seung Bum Lee, Hyun-Ki Kim, Sang Hyuk Park, Ji-Hun Lim, Sang Hyoung Park
    Intestinal Research.2024; 22(1): 75.     CrossRef
  • A novel serum biomarker of endoscopic mucosal healing in inflammatory bowel disease
    Hyoun Woo Kang
    Intestinal Research.2024; 22(1): 3.     CrossRef
  • Management of ulcerative colitis in Taiwan: consensus guideline of the Taiwan Society of Inflammatory Bowel Disease updated in 2023
    Hsu-Heng Yen, Jia-Feng Wu, Horng-Yuan Wang, Ting-An Chang, Chung-Hsin Chang, Chen-Wang Chang, Te-Hsin Chao, Jen-Wei Chou, Yenn-Hwei Chou, Chiao-Hsiung Chuang, Wen-Hung Hsu, Tzu-Chi Hsu, Tien-Yu Huang, Tsung-I Hung, Puo-Hsien Le, Chun-Che Lin, Chun-Chi Lin
    Intestinal Research.2024; 22(3): 213.     CrossRef
  • Histologic improvement predicts endoscopic remission in patients with ulcerative colitis
    Ji Eun Kim, Minjee Kim, Min-Ji Kim, Eun Ran Kim, Sung Noh Hong, Dong Kyung Chang, Sang Yun Ha, Young-Ho Kim
    Scientific Reports.2024;[Epub]     CrossRef
  • Practical management of mild-to-moderate ulcerative colitis: an international expert consensus
    Ferdinando D’Amico, Fernando Magro, Axel Dignass, Sameer Al Awadhi, Ana Gutierrez Casbas, Natália Sousa Freitas Queiroz, Grażyna Rydzewska, Byong Duk Ye, Zhihua Ran, Ailsa Hart, Vipul Jairath, Gionata Fiorino, Laurent Peyrin-Biroulet, Silvio Danese
    Expert Review of Gastroenterology & Hepatology.2024; 18(8): 421.     CrossRef
  • Predictive Value of PHRI for Recurrence within One Year after UC Treatment: A Retrospective Study
    Kun Zhang, Jianlan Xie, Jianmin Zhao, Mei Jia
    British Journal of Hospital Medicine.2024; : 1.     CrossRef
  • Molecular Activity of Inflammation and Epithelial-Mesenchymal Transition in the Microenvironment of Ulcerative Colitis
    Yu Kyung Jun, Nayoung Kim, Hyuk Yoon, Ji Hyun Park, Hyung Kyung Kim, Yonghoon Choi, Ji Ae Lee, Cheol Min Shin, Young Soo Park, Dong Ho Lee
    Gut and Liver.2024; 18(6): 1037.     CrossRef
  • Comparison of Two Types of 1-L Polyethylene Glycol-ascorbic Acid as Colonoscopic Bowel Preparation: A Prospective Randomized Study
    Suh Hyun Choi, Won Eui Yoon, Seung Hyuk Kim, Hee Jun Myung, Seo Hyun Kim, Soon Oh So, Se Hun Kim, Hyun Mi Lee, Yeoun Jung Oh, Jeong Seop Moon, Tae Yeong Park, You Sun Kim
    The Korean Journal of Gastroenterology.2022; 80(2): 85.     CrossRef
  • 4,480 View
  • 383 Download
  • 9 Web of Science
  • 9 Crossref
Close layer
Original Articles
IBD
Factors associated with anti-tumor necrosis factor effectiveness to prevent postoperative recurrence in Crohn’s disease
Anthony Buisson, Lisa Cannon, Konstantin Umanskiy, Roger D. Hurst, Neil H. Hyman, Atsushi Sakuraba, Joel Pekow, Sushila Dalal, Russell D. Cohen, Bruno Pereira, David T. Rubin
Intest Res 2022;20(3):303-312.   Published online August 4, 2021
DOI: https://doi.org/10.5217/ir.2021.00018
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Background/Aims
We assessed the effectiveness of anti-TNF agents and its associated factors to prevent endoscopic and clinical postoperative recurrence (POR) in Crohn’s disease (CD).
Methods
From a prospectively-maintained database, we retrieved 316 CD patients who underwent intestinal resection (2011–2017). Endoscopic (Rutgeerts index ≥ i2 at 6 months) and clinical (recurrence of symptoms leading to hospitalization or therapeutic escalation) POR were assessed.
Results
In 117 anti-TNF-naïve patients, anti-TNF therapy was more effective than immunosuppressive agents (odds ratio [OR], 8.8; 95% confidence interval [CI], 1.8–43.9; P= 0.008) and no medication/5-aminosalicylates (OR, 5.2; 95% CI, 1.0–27.9; P= 0.05) to prevent endoscopic POR. In 199 patients exposed to anti-TNF prior to the surgery, combination with anti-TNF and immunosuppressive agents was more effective than anti-TNF monotherapy (OR, 2.32; 95% CI, 1.02–5.31; P= 0.046) to prevent endoscopic POR. Primary failure to anti-TNF agent prior to surgery was predictive of anti-TNF failure to prevent endoscopic POR (OR, 2.41; 95% CI, 1.10–5.32; P= 0.03). When endoscopic POR despite anti-TNF prophylactic medication (n = 55), optimizing anti-TNF and adding an immunosuppressive drug was the most effective option to prevent clinical POR (hazard ratio, 7.38; 95% CI, 1.54–35.30; P= 0.012). Anti-TNF therapy was the best option to prevent clinical POR (hazard ratio, 3.10; 95% CI, 1.09–8.83; P= 0.034) in patients with endoscopic POR who did not receive any biologic to prevent endoscopic POR (n = 55).
Conclusions
Anti-TNF was the most effective medication to prevent endoscopic and clinical POR. Combination with anti-TNF and immunosuppressive agents should be considered in patients previously exposed to anti-TNF.

Citations

Citations to this article as recorded by  
  • Impact of age at diagnosis on long‐term prognosis in patients with intestinal Behçet's disease
    Ji Young Chang, Soo Jung Park, Jae Jun Park, Tae Il Kim, Jae Hee Cheon, Jihye Park
    Journal of Gastroenterology and Hepatology.2024; 39(3): 519.     CrossRef
  • Postoperative small bowel Crohn's disease: how to diagnose, manage and treat
    Chak Lam Ip, Ray Boyapati, Rahul Kalla
    Current Opinion in Gastroenterology.2024; 40(3): 209.     CrossRef
  • Stapled End-To-Side Ileocolic Anastomosis in Crohn’s Disease: Old Dog, Reliable Tricks? A Retrospective Two-Center Cohort Study
    Volkan Doğru, Jean H. Ashburn, Umut Akova, Alton G. Sutter, Eren Esen, Emily M. Gardner, Andre da Luz Moreira, Arman Erkan, John Kirat, Michael J. Grieco, Feza H. Remzi
    Annals of Surgery Open.2024; 5(1): e374.     CrossRef
  • Clinical Significance of Prognostic Nutrition Index in Patients with Crohn’s Disease after Primary Bowel Resection
    Hyeon Woo Bae, Yong Joon Lee, Min Young Park, Seung Yoon Yang, Yoon Dae Han, Min Soo Cho, Hyuk Hur, Kang Young Lee, Jae Hee Cheon, Joseph C. Carmichael, Byung Soh Min
    Yonsei Medical Journal.2024; 65(7): 380.     CrossRef
  • How Reliable Is Endoscopic Scoring of Postoperative Recurrence in Crohn Disease?: A Systematic Review and Meta-Analysis
    Eline M. L. van der Does de Willebois, Vittoria Bellato, Marjolijn Duijvestein, Susan van Dieren, Silvio Danese, Pierpaolo Sileri, Christianne J. Buskens, Andrea Vignali, Willem A. Bemelman
    Annals of Surgery Open.2024; 5(1): e397.     CrossRef
  • Systematic review: Patient‐related, microbial, surgical, and histopathological risk factors for endoscopic post‐operative recurrence in patients with Crohn's disease
    Michiel T. J. Bak, Karlijn Demers, Nassim Hammoudi, Matthieu Allez, Mark S. Silverberg, Gwenny M. Fuhler, Kaushal Parikh, Marieke J. Pierik, Laurents P. S. Stassen, C. Janneke van der Woude, Michail Doukas, Oddeke van Ruler, Annemarie C. de Vries
    Alimentary Pharmacology & Therapeutics.2024; 60(3): 310.     CrossRef
  • Common Mistakes in Managing Patients with Inflammatory Bowel Disease
    Javier P. Gisbert, María Chaparro
    Journal of Clinical Medicine.2024; 13(16): 4795.     CrossRef
  • Preventing Recurrence of Crohn’s Disease Post-Ileocaecal Surgery in Paediatric Patients: A Therapy Guide Based on Systematic Review of the Evidence
    Jiri Bronsky, Kristyna Zarubova, Michal Kubat, Vojtech Dotlacil
    Pediatric Drugs.2024; 26(6): 659.     CrossRef
  • Anti-TNF Agents and New Biological Agents (Vedolizumab and Ustekinumab) in the Prevention and Treatment of Postoperative Recurrence After Surgery in Crohn’s Disease
    Javier P. Gisbert, María Chaparro
    Drugs.2023; 83(13): 1179.     CrossRef
  • Prevention of postoperative recurrence in Crohn’s disease: the never-ending story
    Jung-Bin Park, Sang Hyoung Park
    Intestinal Research.2022; 20(3): 279.     CrossRef
  • Timing of individualized surgical intervention in Crohn’s disease
    Kai Xia, Ren-Yuan Gao, Xiao-Cai Wu, Lu Yin, Chun-Qiu Chen
    World Journal of Gastrointestinal Surgery.2022; 14(12): 1320.     CrossRef
  • 4,595 View
  • 535 Download
  • 9 Web of Science
  • 11 Crossref
Close layer
IBD
Risk factors for non-reaching of ileal pouch to the anus in laparoscopic restorative proctocolectomy with handsewn anastomosis for ulcerative colitis
Shigenobu Emoto, Keisuke Hata, Hiroaki Nozawa, Kazushige Kawai, Toshiaki Tanaka, Takeshi Nishikawa, Yasutaka Shuno, Kazuhito Sasaki, Manabu Kaneko, Koji Murono, Yuuki Iida, Hiroaki Ishii, Yuichiro Yokoyama, Hiroyuki Anzai, Hirofumi Sonoda, Soichiro Ishihara
Intest Res 2022;20(3):313-320.   Published online March 12, 2021
DOI: https://doi.org/10.5217/ir.2020.00158
AbstractAbstract PDFPubReaderePub
Background/Aims
Restorative proctocolectomy (RPC) with ileal pouch-anal anastomosis and handsewn anastomosis for ulcerative colitis requires pulling down of the ileal pouch into the pelvis, which can be technically challenging. We examined risk factors for the pouch not reaching the anus.
Methods
Clinical records of 62 consecutive patients who were scheduled to undergo RPC with handsewn anastomosis at the University of Tokyo Hospital during 1989–2019 were reviewed. Risk factors for non-reaching were analyzed in patients in whom hand sewing was abandoned for stapled anastomosis because of nonreaching. Risk factors for non-reaching in laparoscopic RPC were separately analyzed. Anatomical indicators obtained from presurgical computed tomography (CT) were also evaluated.
Results
Thirty-seven of 62 cases underwent laparoscopic procedures. In 6 cases (9.7%), handsewn anastomosis was changed to stapled anastomosis because of non-reaching. Male sex and a laparoscopic approach were independent risk factors of non-reaching. Distance between the terminal of the superior mesenteric artery (SMA) ileal branch and the anus > 11 cm was a risk factor for non-reaching.
Conclusions
Laparoscopic RPC with handsewn anastomosis may limit extension and induction of the ileal pouch into the anus. Preoperative CT measurement from the terminal SMA to the anus may be useful for predicting non-reaching.

Citations

Citations to this article as recorded by  
  • Temporary loop end ileostomy reduces the risk of stoma outlet obstruction: a comparative clinical study in patients undergoing restorative proctocolectomy and ileal pouch-anal anastomosis
    Takayuki Ogino, Yuki Sekido, Tsunekazu Mizushima, Makoto Fujii, Ryota Mori, Mitsunobu Takeda, Tsuyoshi Hata, Atsushi Hamabe, Norikatsu Miyoshi, Mamoru Uemura, Yuichiro Doki, Hidetoshi Eguchi
    Surgery Today.2024;[Epub]     CrossRef
  • Preoperative Simulation of Ileal Pouch–Anal Anastomosis in Patients With Ulcerative Colitis Using a 3-Dimensional Printed Model
    Shota Yokose, Koji Murono, Hiroaki Nozawa, Kazuhito Sasaki, Shigenobu Emoto, Hiroyuki Matsuzaki, Yuichiro Yokoyama, Shinya Abe, Yuzo Nagai, Yuichiro Yoshioka, Takahide Shinagawa, Hirofumi Sonoda, Shin Murai, Koichi Komatsu, Soichiro Ishihara
    Inflammatory Bowel Diseases.2023; 29(12): 1865.     CrossRef
  • Preoperative Computed Tomography Indices Predict Non-reach Prior to Ileal Pouch-Anal Anastomosis
    Evan D. Adams, Charlotte A Lansky, Cindy E. Kallman, Karen N. Zaghiyan, Phillip R. Fleshner
    Diseases of the Colon & Rectum.2023;[Epub]     CrossRef
  • Laparoscopic vs open restorative proctectomy after total abdominal colectomy for ulcerative colitis or familial adenomatous polyposis
    Hiroaki Nozawa, Keisuke Hata, Kazuhito Sasaki, Koji Murono, Kazushige Kawai, Shigenobu Emoto, Soichiro Ishihara
    Langenbeck's Archives of Surgery.2022; 407(4): 1605.     CrossRef
  • Recent Advance in the Management of Dysplasia in the Ulcerative Colitis
    Dong-Hoon Yang
    Journal of Digestive Cancer Reports.2021; 9(2): 50.     CrossRef
  • 5,894 View
  • 516 Download
  • 4 Web of Science
  • 5 Crossref
Close layer
IBD
Evaluation of nutritional status using bioelectrical impedance analysis in patients with inflammatory bowel disease
Seung Hyuk Kim, You Sun Kim, Si Hyeong Lee, Hyun Mi Lee, Won Eui Yoon, Seo Hyun Kim, Hee Jun Myung, Jeong Seop Moon
Intest Res 2022;20(3):321-328.   Published online July 20, 2021
DOI: https://doi.org/10.5217/ir.2021.00022
AbstractAbstract PDFPubReaderePub
Background/Aims
Nutritional status influences quality of life among patients with inflammatory bowel disease (IBD), although there is no clear method to evaluate nutritional status in this setting. Therefore, this study examined whether bioelectrical impedance analysis (BIA) could be used to evaluate the nutritional status of patients with IBD.
Methods
We retrospectively analyzed data from 139 Korean patients with IBD who were treated between November 2018 and November 2019. Patients were categorized as having active or inactive IBD based on the Harvey-Bradshaw index (a score of ≥5 indicates active Crohn’s disease) and the partial Mayo scoring index (a score of ≥2 indicates active ulcerative colitis). BIA results and serum nutritional markers were analyzed according to disease activity.
Results
The mean patient age was 45.11±17.71 years. The study included 47 patients with ulcerative colitis and 92 patients with Crohn’s disease. Relative to the group with active disease (n=72), the group with inactive disease (n=67) had significantly higher values for hemoglobin (P<0.001), total protein (P<0.001), and albumin (P<0.001). Furthermore, the group with inactive disease had higher BIA values for body moisture (P=0.047), muscle mass (P=0.046), skeletal muscle mass (P=0.042), body mass index (P=0.027), and mineral content (P=0.034). Moreover, the serum nutritional markers were positively correlated with the BIA results.
Conclusions
Nutritional markers evaluated using BIA were correlated with serum nutritional markers and inversely correlated with disease activity. Therefore, we suggest that BIA may be a useful tool that can help existing nutritional tests monitor the nutritional status of IBD patients.

Citations

Citations to this article as recorded by  
  • Comparison of body composition change, measured with bioelectrical impedance analysis, between singleton and twin pregnancy: A prospective cohort study
    Bo Young Choi, Sae Yeon Jung, Hee Kyeong Lee, Min Jung Lee, Hyeon Ji Kim, Jee Yoon Park, Kyung Joon Oh
    European Journal of Obstetrics & Gynecology and Reproductive Biology.2025; 306: 154.     CrossRef
  • BODY FAT COMPOSITION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES: A COMPARATIVE STUDY BETWEEN SKINFOLDS AND ULTRASONOGRAPHY
    Isadora Sayuri Macedo TUMA, Maria Paula Carlin CAMBI, Thyago Proença de MORAES, Daniéla Oliveira MAGRO, Paulo Gustavo KOTZE
    Arquivos de Gastroenterologia.2024;[Epub]     CrossRef
  • Navigating the Intersection: Sarcopenia and Sarcopenic Obesity in Inflammatory Bowel Disease
    Valentin Calvez, Guia Becherucci, Carlo Covello, Giulia Piccirilli, Irene Mignini, Giorgio Esposto, Lucrezia Laterza, Maria Elena Ainora, Franco Scaldaferri, Antonio Gasbarrini, Maria Assunta Zocco
    Biomedicines.2024; 12(6): 1218.     CrossRef
  • Association between inflammatory bowel disease and osteoporosis in European and East Asian populations: exploring causality, mediation by nutritional status, and shared genetic architecture
    Jian Kang, Xize Wu, Yue Li, Shuangli Zhao, Shixuan Wang, Dongdong Yu
    Frontiers in Immunology.2024;[Epub]     CrossRef
  • Micronutrient Deficiency and Muscular Status in Inflammatory Bowel Disease
    Joonhee Han, Hyun Joo Song, Min Sook Kang, Hogyung Jun, Heung Up Kim, Ki Soo Kang, Donghyoun Lee
    Nutrients.2024; 16(21): 3763.     CrossRef
  • Evaluation of Nutritional Characteristics Reveals Similar Prevalence of Malnutrition in Patients with Ulcerative Colitis and Crohn’s Disease
    Arshdeep Singh, Vandana Midha, Ramit Mahajan, Shruti Verma, Chandan Kakkar, Jasmine Grover, Dharmatma Singh, Ramandeep Kaur, Abhishek Masih, Namita Bansal, Catherine Wall, Ajit Sood
    Digestive Diseases and Sciences.2023; 68(2): 580.     CrossRef
  • Response to Ustekinumab Therapy Is Associated with an Improvement of Nutritional Status in Patients with Crohn’s Disease
    Lorenzo Bertani, Claudia D’Alessandro, Marco Fornili, Francesca Coppini, Federico Zanzi, Luca Carmisciano, Francesca Geri, Giovanni Baiano Svizzero, Emma Maria Rosi, Alice De Bernardi, Linda Ceccarelli, Maria Gloria Mumolo, Laura Baglietto, Massimo Bellin
    Journal of Clinical Medicine.2023; 12(19): 6118.     CrossRef
  • Clinical Implications of Dietary Probiotic Supplement (Associated with L-Glutamine and Biotin) in Ulcerative Colitis Patients’ Body Composition and Quality of Life
    Flavia Maria Pavel, Simona Gabriela Bungau, Delia Mirela Tit, Timea Claudia Ghitea, Ruxandra Cristina Marin, Andrei-Flavius Radu, Radu Dumitru Moleriu, Tiberia Ilias, Cristian Bustea, Cosmin Mihai Vesa
    Nutrients.2023; 15(24): 5049.     CrossRef
  • 5,811 View
  • 545 Download
  • 8 Web of Science
  • 8 Crossref
Close layer
IBD
Real-world data for golimumab treatment in patients with ulcerative colitis in Japan: interim analysis in post-marketing surveillance
Shiro Nakamura, Teita Asano, Hiroaki Tsuchiya, Kanami Sugimoto, Yuya Imai, Seiji Yokoyama, Yasuo Suzuki
Intest Res 2022;20(3):329-341.   Published online August 4, 2021
DOI: https://doi.org/10.5217/ir.2021.00032
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Background/Aims
Golimumab (GLM) is an anti-tumor necrosis factor-α drug approved for treating moderate-to-severe active ulcerative colitis (UC). A 52-week post-marketing surveillance (PMS) was initiated to evaluate its safety and effectiveness in patients with UC in Japan. We present an interim report of the ongoing PMS.
Methods
Patients received 200 mg of subcutaneous GLM at week 0, 100 mg at week 2, and 100 mg 4 weekly thereafter. The safety analysis set included 392 patients with UC, and the effectiveness analysis set 387 patients. Safety and effectiveness were assessed at week 6.
Results
Adverse drug reactions (ADRs) were reported in 8.2% (32/392) and serious ADRs in 4.6% (18/392). The most frequent ADRs were infection and infestation (3.3%), with herpes zoster being the most common. ADRs were significantly higher in patients with concomitant corticosteroid use (odds ratio [OR], 3.45; 95% confidence interval [CI], 1.40–9.68). No significant difference in ADR incidence was observed between patients aged ≥65 and <65 years (OR, 1.23; 95% CI, 0.35–3.47). Six-week effectiveness of GLM was confirmed by a decrease in the partial Mayo score (–2.3; 95% CI, –2.6 to –2.1) and C-reactive protein levels (–0.64; 95% CI, –0.92 to –0.36), including in the biologics-experienced population.
Conclusions
The safety and effectiveness of GLM at week 6 in a real-world setting were demonstrated in patients with UC in Japan. ADR patterns were consistent with previous reports with no new safety signals. Concomitant corticosteroid use may be associated with increased ADR incidence. The final results of the ongoing PMS are necessary for further evaluation.

Citations

Citations to this article as recorded by  
  • Real-world effectiveness and safety of advanced therapies for the treatment of moderate-to-severe ulcerative colitis: Evidence from a systematic literature review
    Peter M. Irving, Peter Hur, Raju Gautam, Xiang Guo, Severine Vermeire
    Journal of Managed Care & Specialty Pharmacy.2024; 30(9): 1026.     CrossRef
  • Reviewing not Homer’s Iliad, but “Kai Bao Ben Cao”: indigo dye—the past, present, and future
    Yusuke Yoshimatsu, Tomohisa Sujino, Takanori Kanai
    Intestinal Research.2023; 21(2): 174.     CrossRef
  • Golimumab for Ulcerative Colitis: One More Option to SAVE the Colon
    Sang Hyoung Park
    Crohn's & Colitis 360.2023;[Epub]     CrossRef
  • Advancements in the Management of Moderate-to-Severe Ulcerative Colitis: A Revised 2023 Korean Treatment Guidelines
    Soo-Young Na
    The Korean Journal of Medicine.2023; 98(5): 223.     CrossRef
  • Pharmacogenetics-based personalized treatment in patients with inflammatory bowel disease: A review
    Ji Young Chang, Jae Hee Cheon
    Precision and Future Medicine.2021; 5(4): 151.     CrossRef
  • 5,583 View
  • 670 Download
  • 4 Web of Science
  • 5 Crossref
Close layer
IBD
A nationwide analysis on the influence of obesity in inflammatory bowel disease hospitalizations
Dushyant Singh Dahiya, Asim Kichloo, Farah Wani, Jagmeet Singh, Dhanshree Solanki, Hafeez Shaka
Intest Res 2022;20(3):342-349.   Published online May 21, 2021
DOI: https://doi.org/10.5217/ir.2021.00046
AbstractAbstract PDFPubReaderePub
Background/Aims
Proinflammatory cytokines released from adipocytes can influence the development, progression, and treatment of inflammatory bowel disease (IBD), and may be associated with worse clinical outcomes.
Methods
For 2016–2018, we analyzed data from the Nationwide Inpatient Sample to identify adult (≥18 years) hospitalizations with a primary discharge diagnosis of IBD. The study sample was divided based on the presence or absence of obesity. The primary outcomes included inpatient mortality, while the secondary outcomes consisted of system-based complications and disease implications on the United States healthcare system.
Results
We identified 282,005 hospitalizations of IBD from 2016 to 2018. Of these hospitalizations, 26,465 (9.4%) had a secondary diagnosis of obesity while 255,540 (90.6%) served as controls. IBD hospitalizations with obesity had a higher mean age (47.9 years vs. 45.2 years, P<0.001), middle age (range, 40–65 years) predominance (37.7% vs. 28.9%, P<0.001), female predominance (64.1% vs. 52.5%, P<0.001) and higher proportion of patients with comorbidities compared to the non-obese cohort. White predominance was observed in both subgroups. No difference in the odds of inpatient mortality was noted between the 2 subgroups; however, IBD hospitalizations with obesity had higher mean total hospital charge ($50,126 vs. $45,001, P<0.001), longer length of stay (5.5 days vs. 4.9 days, P<0.001) and higher proportion of complications compared to the non-obese cohort.
Conclusions
Obese IBD hospitalizations had higher length of stay, total hospital charge, and complications compared to the non-obese cohort.

Citations

Citations to this article as recorded by  
  • Obesity and Chronic Inflammation: Implications for Rheumatoid Arthritis, Spondyloarthritis, and Ulcerative Colitis
    Ada Corrado, Ilaria Guadagni, Giovanna Picarelli, Angela Variola
    Immunity, Inflammation and Disease.2025;[Epub]     CrossRef
  • Recomendaciones sobre el manejo de la obesidad grave en pacientes con enfermedad inflamatoria intestinal del Grupo Español de Trabajo en Enfermedad Inflamatoria Intestinal (GETECCU), Sociedad Española de Obesidad (SEEDO), Asociación Española de Cirugía (A
    Eugeni Domènech, Andreea Ciudin, José María Balibrea, Eduard Espinet-Coll, Fiorella Cañete, Lilliam Flores, Manuel Ferrer-Márquez, Román Turró, Alejandro Hernández-Camba, Yamile Zabana, Ana Gutiérrez, José María Balibrea, Manuel Barreiro-de Acosta, Javier
    Gastroenterología y Hepatología.2024; 47(8): 906.     CrossRef
  • The Rising Epidemic of Obesity in Patients with Inflammatory Bowel Disease
    Jellyana Peraza, Erin Abbott, Mark Shneyderman, Asher Kornbluth, Maitreyi Raman, Stephanie Gold
    Current Treatment Options in Gastroenterology.2024; 22(3): 134.     CrossRef
  • Recommendations on the management of severe obesity in patients with inflammatory bowel disease of the Spanish Group on Crohn’s Disease and Ulcerative Colitis (GETECCU), Spanish Society of Obesity (SEEDO), Spanish Association of Surgery (AEC) and Spanish
    Eugeni Domènech, Andreea Ciudin, José María Balibrea, Eduard Espinet-Coll, Fiorella Cañete, Lilliam Flores, Manuel Ferrer-Márquez, Román Turró, Alejandro Hernández-Camba, Yamile Zabana, Ana Gutiérrez, José María Balibrea, Manuel Barreiro-de Acosta, Javier
    Gastroenterología y Hepatología (English Edition).2024; 47(8): 906.     CrossRef
  • Body Mass Index Profile of Adult Patients with Inflammatory Bowel Disease in a Multicenter Study in Northeastern Brazil
    Jones Lima, Carlos Brito, Lívia Celani, Marcelo Vicente Araújo, Maurilio Lucena, Graciana Vasconcelos, Gustavo Lima, Fernando Nóbrega, George Diniz, Norma Lucena-Silva, Regiane Maio, Valéria Martinelli
    Clinical and Experimental Gastroenterology.2023; Volume 16: 213.     CrossRef
  • Clinical outcomes and predictors of response for adalimumab in patients with moderately to severely active ulcerative colitis: a KASID prospective multicenter cohort study
    Seung Yong Shin, Soo Jung Park, Young Kim, Jong Pil Im, Hyo Jong Kim, Kang-Moon Lee, Ji Won Kim, Sung-Ae Jung, Jun Lee, Sang-Bum Kang, Sung Jae Shin, Eun Sun Kim, You Sun Kim, Tae Oh Kim, Hyun-Soo Kim, Dong Il Park, Hyung Kil Kim, Eun Soo Kim, Young-Ho Ki
    Intestinal Research.2022; 20(3): 350.     CrossRef
  • 5,632 View
  • 500 Download
  • 4 Web of Science
  • 6 Crossref
Close layer
IBD
Clinical outcomes and predictors of response for adalimumab in patients with moderately to severely active ulcerative colitis: a KASID prospective multicenter cohort study
Seung Yong Shin, Soo Jung Park, Young Kim, Jong Pil Im, Hyo Jong Kim, Kang-Moon Lee, Ji Won Kim, Sung-Ae Jung, Jun Lee, Sang-Bum Kang, Sung Jae Shin, Eun Sun Kim, You Sun Kim, Tae Oh Kim, Hyun-Soo Kim, Dong Il Park, Hyung Kil Kim, Eun Soo Kim, Young-Ho Kim, Do Hyun Kim, Dennis Teng, Jong-Hwa Kim, Wonyong Kim, Chang Hwan Choi, on behalf of the IBD Research Group of the Korean Association for the Study of Intestinal Diseases
Intest Res 2022;20(3):350-360.   Published online July 23, 2021
DOI: https://doi.org/10.5217/ir.2021.00049
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Background/Aims
This study assessed the efficacy and safety of adalimumab (ADA) and explored predictors of response in Korean patients with ulcerative colitis (UC).
Methods
A prospective, observational, multicenter study was conducted over 56 weeks in adult patients with moderately to severely active UC who received ADA. Clinical response, remission, and mucosal healing were assessed using the Mayo score.
Results
A total of 146 patients were enrolled from 17 academic hospitals. Clinical response rates were 52.1% and 37.7% and clinical remission rates were 24.0% and 22.0% at weeks 8 and 56, respectively. Mucosal healing rates were 39.0% and 30.1% at weeks 8 and 56, respectively. Prior use of anti-tumor necrosis factor-α (anti-TNF-α) did not affect clinical and endoscopic responses. The ADA drug level was significantly higher in patients with better outcomes at week 8 (P<0.05). In patients with lower endoscopic activity, higher body mass index, and higher serum albumin levels at baseline, the clinical response rate was higher at week 8. In patients with lower Mayo scores and C-reactive protein levels, clinical responses, and mucosal healing at week 8, the clinical response rate was higher at week 56. Serious adverse drug reactions were identified in 2.8% of patients.
Conclusions
ADA is effective and safe for induction and maintenance in Korean patients with UC, regardless of prior anti-TNF-α therapy. The ADA drug level is associated with the efficacy of induction therapy. Patients with better short-term outcomes were predictive of those with an improved long-term response.

Citations

Citations to this article as recorded by  
  • Prospective Observational Evaluation of the Time-Dependency of Adalimumab Immunogenicity and Drug Concentration in Ulcerative Colitis Patients: the POETIC II Study
    Sivan Harnik, Chaya M Abitbol, Ola Haj Natour, Miri Yavzori, Ella Fudim, Orit Picard, Timna Naftali, Efrat Broide, Ayal Hirsch, Limor Selinger, Eyal Shachar, Doron Yablecovitch, Ahmad Albshesh, Daniel Coscas, Uri Kopylov, Rami Eliakim, Shomron Ben-Horin,
    Journal of Crohn's and Colitis.2024; 18(3): 341.     CrossRef
  • Rapidly achieving clinical remission in ulcerative colitis indicates better endoscopic and histological outcomes
    Rirong Chen, Yizhe Tie, Yongle Huang, Xi Zhang, Zhirong Zeng, Minhu Chen, Li Li, Shenghong Zhang
    United European Gastroenterology Journal.2024; 12(4): 459.     CrossRef
  • Effectiveness of adalimumab in severe ulcerative colitis: A systematic review and a meta‐analysis
    Saleh Azadbakht, Masomeh Seighali, Salehe Azadbakht, Morteza Azadbakht
    Health Science Reports.2024;[Epub]     CrossRef
  • Dynamic changes in the gut microbiota composition during adalimumab therapy in patients with ulcerative colitis: implications for treatment response prediction and therapeutic targets
    Han Na Oh, Seung Yong Shin, Jong-Hwa Kim, Jihye Baek, Hyo Jong Kim, Kang-Moon Lee, Soo Jung Park, Seok-Young Kim, Hyung-Kyoon Choi, Wonyong Kim, Woo Jun Sul, Chang Hwan Choi
    Gut Pathogens.2024;[Epub]     CrossRef
  • Real-world effectiveness and safety of advanced therapies for the treatment of moderate-to-severe ulcerative colitis: Evidence from a systematic literature review
    Peter M. Irving, Peter Hur, Raju Gautam, Xiang Guo, Severine Vermeire
    Journal of Managed Care & Specialty Pharmacy.2024; 30(9): 1026.     CrossRef
  • Korean clinical practice guidelines on biologics and small molecules for moderate-to-severe ulcerative colitis
    Soo-Young Na, Chang Hwan Choi, Eun Mi Song, Ki Bae Bang, Sang Hyoung Park, Eun Soo Kim, Jae Jun Park, Bora Keum, Chang Kyun Lee, Bo-In Lee, Seung-Bum Ryoo, Seong-Joon Koh, Miyoung Choi, Joo Sung Kim
    Intestinal Research.2023; 21(1): 61.     CrossRef
  • Changes in fecal metabolic and lipidomic features by anti-TNF treatment and prediction of clinical remission in patients with ulcerative colitis
    Seok-Young Kim, Seung Yong Shin, Soo Jung Park, Jong Pil Im, Hyo Jong Kim, Kang-Moon Lee, Ji Won Kim, Sung-Ae Jung, Jun Lee, Sang-Bum Kang, Sung Jae Shin, Eun Sun Kim, You Sun Kim, Tae Oh Kim, Hyun-Soo Kim, Dong Il Park, Hyung Kil Kim, Eun Soo Kim, Young-
    Therapeutic Advances in Gastroenterology.2023;[Epub]     CrossRef
  • Reviewing not Homer’s Iliad, but “Kai Bao Ben Cao”: indigo dye—the past, present, and future
    Yusuke Yoshimatsu, Tomohisa Sujino, Takanori Kanai
    Intestinal Research.2023; 21(2): 174.     CrossRef
  • Precision medicine and drug optimization in adult inflammatory bowel disease patients
    Sophie Vieujean, Edouard Louis
    Therapeutic Advances in Gastroenterology.2023;[Epub]     CrossRef
  • Real-world effectiveness and safety of adalimumab in Korean patients with intestinal Behcet’s disease: a Korean Association for the Study of Intestinal Diseases (KASID) multicenter study
    Seung Bum Lee, Hee Seung Hong, Chang Kyun Lee, Bo-In Lee, Sol Kim, Seong-Joon Koh, Hosun Yu, Jung-Bin Park, Sung Wook Hwang, Byong Duk Ye, Suk-Kyun Yang, Sang Hyoung Park
    The Korean Journal of Internal Medicine.2023; 38(5): 661.     CrossRef
  • Advancements in the Management of Moderate-to-Severe Ulcerative Colitis: A Revised 2023 Korean Treatment Guidelines
    Soo-Young Na
    The Korean Journal of Medicine.2023; 98(5): 223.     CrossRef
  • Prediction of Clinical Remission with Adalimumab Therapy in Patients with Ulcerative Colitis by Fourier Transform–Infrared Spectroscopy Coupled with Machine Learning Algorithms
    Seok-Young Kim, Seung Yong Shin, Maham Saeed, Ji Eun Ryu, Jung-Seop Kim, Junyoung Ahn, Youngmi Jung, Jung Min Moon, Chang Hwan Choi, Hyung-Kyoon Choi
    Metabolites.2023; 14(1): 2.     CrossRef
  • Association of C-reactive Protein and Partial Mayo Score With Response to Tofacitinib Induction Therapy: Results From the Ulcerative Colitis Clinical Program
    Marla C Dubinsky, Fernando Magro, Flavio Steinwurz, David P Hudesman, Jami A Kinnucan, Ryan C Ungaro, Markus F Neurath, Nicole Kulisek, Jerome Paulissen, Chinyu Su, Dario Ponce de Leon, Miguel Regueiro
    Inflammatory Bowel Diseases.2022;[Epub]     CrossRef
  • Effectiveness and Safety of Golimumab in Patients with Ulcerative Colitis: A Multicenter, Prospective, Postmarketing Surveillance Study
    Jongwook Yu, Soo Jung Park, Hyung Wook Kim, Yun Jeong Lim, Jihye Park, Jae Myung Cha, Byong Duk Ye, Tae Oh Kim, Hyun-Soo Kim, Hyun Seok Lee, Su Young Jung, Youngdoe Kim, Chang Hwan Choi
    Gut and Liver.2022; 16(5): 764.     CrossRef
  • Pharmacogenetics-based personalized treatment in patients with inflammatory bowel disease: A review
    Ji Young Chang, Jae Hee Cheon
    Precision and Future Medicine.2021; 5(4): 151.     CrossRef
  • 8,214 View
  • 661 Download
  • 17 Web of Science
  • 15 Crossref
Close layer
IBD
Intestinal ultrasonography and fecal calprotectin for monitoring inflammation of ileal Crohn’s disease: two complementary tests
José María Paredes, Tomás Ripollés, Ángela Algarra, Rafael Diaz, Nadia Moreno, Patricia Latorre, María Jesús Martínez, Pilar Llopis, Antonio López, Eduardo Moreno-Osset
Intest Res 2022;20(3):361-369.   Published online March 15, 2022
DOI: https://doi.org/10.5217/ir.2021.00126
AbstractAbstract PDFPubReaderePub
Background/Aims
Tight control of inflammation and adjustment of treatment if activity persists is the current strategy for the management of Crohn’s disease (CD). The usefulness of fecal calprotectin (FC) in isolated involvement of the small intestine in CD is controversial. To assess the usefulness of FC to determine the inflammatory activity detected by intestinal ultrasonography (IUS) in ileal CD.
Methods
Patients with exclusively ileal involvement CD who underwent IUS and an FC were prospectively included. Simple ultrasound index was used to determine inflammatory activity. The usual statistical tests for comparison of diagnostic techniques were used.
Results
One hundred and five patients were included, IUS showed inflammatory activity in 59% of patients and complications in 18.1%. FC showed a significant correlation with IUS in the weak range (Spearman coefficient r=0.502; P<0.001); the area under the receiver operating characteristic curve was 0.79 (95% confidence interval, 0.70–0.88; P<0.001). The FC value that best reflected the activity in IUS was 100 μg/g with sensitivity, specificity, and positive and negative predictive values of 73.0%, 71.4%, 79.3% and 63.8%, respectively. There were no differences in FC concentration between patients with or without transmural complications. The addition of serum C-reactive protein to FC did not improve the ability to assess IUS activity.
Conclusions
FC has a significant correlation with IUS to monitor ileal CD activity. This correlation is weak and it does not allow assessing the presence of CD complications. Both tests should be used in conjunction for tight control of ileal CD. More studies on noninvasive tests in this location are needed.

Citations

Citations to this article as recorded by  
  • Fecal calprotectin, intestinal ultrasound, and their combination for the diagnosis of inflammatory bowel disease
    Serge Dubian, Clara Yzet, Franck Brazier, Thierry Yzet, Vincent Hautefeuille, Catherine Decrombecque, Quentin Bocquillon, Nicolas Richard, Anthony Buisson, Jonathan Meynier, Mathurin Fumery
    Clinics and Research in Hepatology and Gastroenterology.2025; 49(3): 102549.     CrossRef
  • Novelties and Perspectives of Intestinal Ultrasound in the Personalised Management of Patients with Inflammatory Bowel Diseases—A Systematic Review
    Vasile-Claudiu Mihai, Liliana Gheorghe, Ioana-Irina Rezuș, Alina Ecaterina Jucan, Mihaela-Cristiana Andronic, Otilia Gavrilescu, Mihaela Dranga, Andrei-Mihai Andronic, Cristina Cijevschi Prelipcean, Ciprian Rezuș, Cătălina Mihai
    Diagnostics.2024; 14(8): 812.     CrossRef
  • The intestinal ultrasound role in inflammatory bowel disease in clinical practice and a critical appraisal of the current guidelines (mini-review)
    Sarah El-Nakeep
    The Egyptian Journal of Internal Medicine.2024;[Epub]     CrossRef
  • Intestinal Ultrasonography as an Alternative to Fecal Calprotectin to Monitor Patients with Crohn’s Disease: Experience from a Novice Sonographer
    Kelly Mathieu, Jérémy Junda, Régine Minet-Quinard, Dilek Coban, Marie Dodel, Bruno Pereira, Anthony Buisson
    Digestive Diseases and Sciences.2024; 69(9): 3402.     CrossRef
  • Intestinal ultrasound for follow-up after 24 weeks of biological therapy in inflammatory bowel disease patients: an Egyptian center experience during the COVID-19 pandemic
    Sarah El-Nakeep, Ehab Nashaat, Fatma Alsherif, Mohamed Magdy Salama
    Egyptian Journal of Radiology and Nuclear Medicine.2024;[Epub]     CrossRef
  • Assessing Active Bowel Inflammation in Crohn's Disease Using Intestinal Ultrasound
    Myung‐won You, Sung Kyoung Moon, Yong Dae Lee, Shin Ju Oh, Seong Jin Park, Chang Kyun Lee
    Journal of Ultrasound in Medicine.2023; 42(12): 2791.     CrossRef
  • Standardizing Endoscopic Reporting in Patients with IBD: JEDII™ to the Rescue?
    Sara Massironi, Alice Laffusa, Tommaso Lorenzo Parigi, Silvio Danese
    Digestive Diseases and Sciences.2023; 68(12): 4287.     CrossRef
  • Application of transabdominal ultrasound in Crohn’s disease
    Wei-Jie Chen, Lei-Lei Luo, Zhi-Xing Dong, Jing Wu, Xing-Xing Gu, Zhao-Lian Bian
    World Chinese Journal of Digestology.2022; 30(8): 364.     CrossRef
  • Is radiological healing alone enough? ‘Can’t take my eyes off’ the mucosa
    Su Hyun Park, Sang Hyoung Park
    The Korean Journal of Internal Medicine.2022; 37(3): 551.     CrossRef
  • 4,235 View
  • 359 Download
  • 7 Web of Science
  • 9 Crossref
Close layer
Microbiota
Relationship between the gut microbiota and bile acid composition in the ileal mucosa of Crohn’s disease
Shigeki Bamba, Osamu Inatomi, Atsushi Nishida, Masashi Ohno, Takayuki Imai, Kenichiro Takahashi, Yuji Naito, Junichi Iwamoto, Akira Honda, Naohiro Inohara, Akira Andoh
Intest Res 2022;20(3):370-380.   Published online May 14, 2021
DOI: https://doi.org/10.5217/ir.2021.00054
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Background/Aims
Crosstalk between the gut microbiota and bile acid plays an important role in the pathogenesis of gastrointestinal disorders. We investigated the relationship between microbial structure and bile acid metabolism in the ileal mucosa of Crohn’s disease (CD).
Methods
Twelve non-CD controls and 38 CD patients in clinical remission were enrolled. Samples were collected from the distal ileum under balloon-assisted enteroscopy. Bile acid composition was analyzed by liquid chromatography-mass spectrometry. The gut microbiota was analyzed by 16S rRNA gene sequencing.
Results
The Shannon evenness index was significantly lower in endoscopically active lesions than in non-CD controls. β-Diversity, evaluated by the UniFrac metric, revealed a significant difference between the active lesions and non-CD controls (P=0.039). The relative abundance of Escherichia was significantly higher and that of Faecalibacterium and Roseburia was significantly lower in CD samples than in non-CD controls. The increased abundance of Escherichia was more prominent in active lesions than in inactive lesions. The proportion of conjugated bile acids was significantly higher in CD patients than in non-CD controls, but there was no difference in the proportion of primary or secondary bile acids. The genera Escherichia and Lactobacillus were positively correlated with the proportion of conjugated bile acids. On the other hand, Roseburia, Intestinibacter, and Faecalibacterium were negatively correlated with the proportion of conjugated bile acids.
Conclusions
Mucosa-associated dysbiosis and the alteration of bile acid composition were identified in the ileum of CD patients. These may play a role in the pathophysiology of ileal lesions in CD patients.

Citations

Citations to this article as recorded by  
  • hUCMSCs Regulate Bile Acid Metabolism to Prevent Heart Failure–Induced Intestinal Injury by Inhibiting the Activation of the STAT3/NF‐κB/MAPK Signaling Pathway via TGR5
    Zetian Wang, Wei Luo, Qing Wang, Chunzheng Liu, Yanshan Gong, Baitian Li, Xuejiao Zeng, Jiaqi Lin, Zehua Su, Xin Li, Yongze Yu, Zhongmin Liu, Ling Gao, Lijun Liao
    Food Frontiers.2025; 6(1): 575.     CrossRef
  • A critical review on inflammatory bowel diseases risk factors, dietary nutrients regulation and protective pathways based on gut microbiota during recent 5 years
    Pengkui Xia, Tao Hou, Hong Jin, Yaqi Meng, Jing Li, Fuchao Zhan, Fang Geng, Bin Li
    Critical Reviews in Food Science and Nutrition.2024; 64(24): 8805.     CrossRef
  • Gut microbiota disparities between active Crohn's disease and healthy controls: A global systematic review
    Rupa Tharu, Geetika Malik Ahlawat, Savitesh Kushwaha, Poonam Khanna
    Clinical Epidemiology and Global Health.2024; 25: 101497.     CrossRef
  • Gut microbes improve prognosis of Klebsiella pneumoniae pulmonary infection through the lung-gut axis
    Yuxiu Tang, Liquan Chen, Jin Yang, Suqing Zhang, Jun Jin, Yao Wei
    Frontiers in Cellular and Infection Microbiology.2024;[Epub]     CrossRef
  • Integrated Analysis of Microbiome and Metabolome Reveals Disease-Specific Profiles in Inflammatory Bowel Diseases and Intestinal Behçet’s Disease
    Yehyun Park, Jae Bum Ahn, Da Hye Kim, I Seul Park, Mijeong Son, Ji Hyung Kim, Hyun Woo Ma, Seung Won Kim, Jae Hee Cheon
    International Journal of Molecular Sciences.2024; 25(12): 6697.     CrossRef
  • Gut Bacterial Composition and Nutritional Implications in Mexican and Spanish Individuals with Inflammatory Bowel Disease Compared to Healthy Controls
    Ricardo García-Gamboa, Osiris Díaz-Torres, Misael Sebastián Gradilla-Hernández, Vicente Pérez-Brocal, Andrés Moya, Marisela González-Avila
    International Journal of Molecular Sciences.2024; 25(22): 11887.     CrossRef
  • Bile acid–induced metabolic changes in the colon promote Enterobacteriaceae expansion and associate with dysbiosis in Crohn’s disease
    Ravi Holani, Haggai Bar-Yoseph, Zakhar Krekhno, Antonio Serapio-Palacios, Kyung-Mee Moon, Richard G. Stacey, Katherine A. Donald, Wanyin Deng, Brian Bressler, Armando A. Magaña, Leonard J. Foster, Michael G. Atser, James D. Johnson, Barton Finlay
    Science Signaling.2024;[Epub]     CrossRef
  • Compositional changes in fecal microbiota associated with clinical phenotypes and prognosis in Korean patients with inflammatory bowel disease
    Seung Yong Shin, Young Kim, Won-Seok Kim, Jung Min Moon, Kang-Moon Lee, Sung-Ae Jung, Hyesook Park, Eun Young Huh, Byung Chang Kim, Soo Chan Lee, Chang Hwan Choi
    Intestinal Research.2023; 21(1): 148.     CrossRef
  • Meta-Analysis Reveals Compositional and Functional Microbial Changes Associated with Osteoporosis
    Oluwamayowa S. Akinsuyi, Luiz F. W. Roesch, Olubukola Oluranti Babalola
    Microbiology Spectrum.2023;[Epub]     CrossRef
  • Crohn’s disease: Why the ileum?
    Nicolas Richard, Guillaume Savoye, Mathilde Leboutte, Asma Amamou, Subrata Ghosh, Rachel Marion-Letellier
    World Journal of Gastroenterology.2023; 29(21): 3222.     CrossRef
  • The Emerging Role of Raman Spectroscopy as an Omics Approach for Metabolic Profiling and Biomarker Detection toward Precision Medicine
    Gabriel Cutshaw, Saji Uthaman, Nora Hassan, Siddhant Kothadiya, Xiaona Wen, Rizia Bardhan
    Chemical Reviews.2023; 123(13): 8297.     CrossRef
  • Current insights on the roles of gut microbiota in inflammatory bowel disease-associated extra-intestinal manifestations: pathophysiology and therapeutic targets
    Yizhe Tie, Yongle Huang, Rirong Chen, Li Li, Minhu Chen, Shenghong Zhang
    Gut Microbes.2023;[Epub]     CrossRef
  • Comments on Efficacy of a Synbiotic Containing Lactobacillus paracasei DKGF1 and Opuntia humifusa in Elderly Patients with Irritable Bowel Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial
    Kwang Woo Kim
    Gut and Liver.2023; 17(6): 954.     CrossRef
  • Evaluation of gut dysbiosis using serum and fecal bile acid profiles
    Tadakuni Monma, Junichi Iwamoto, Hajime Ueda, Makoto Tamamushi, Fumio Kakizaki, Naoki Konishi, Shoichiro Yara, Teruo Miyazaki, Takeshi Hirayama, Tadashi Ikegami, Akira Honda
    World Journal of Clinical Cases.2022; 10(34): 12484.     CrossRef
  • Microbial Modulation in Inflammatory Bowel Diseases
    Jongwook Yu, Jae Hee Cheon
    Immune Network.2022;[Epub]     CrossRef
  • 7,162 View
  • 590 Download
  • 17 Web of Science
  • 15 Crossref
Close layer
Brief Communication
IBD
Colonic oncostatin M expression evaluated by immunohistochemistry and infliximab therapy outcome in corticosteroid-refractory acute severe ulcerative colitis
Jim O’Connell, Jayne Doherty, Amy Buckley, David Cormican, Cara Dunne, Karen Hartery, John Larkin, Finbar MacCarthy, Paul McCormick, Susan McKiernan, Brian Mehigan, Cian Muldoon, Ciara Ryan, Jacintha O’Sullivan, David Kevans
Intest Res 2022;20(3):381-385.   Published online March 11, 2022
DOI: https://doi.org/10.5217/ir.2021.00073
PDFSupplementary MaterialPubReaderePub

Citations

Citations to this article as recorded by  
  • Role of Oncostatin M in the prognosis of inflammatory bowel disease: A meta-analysis
    Yue Yang, Kan-Zuo Fu, Gu Pan
    World Journal of Gastrointestinal Surgery.2024; 16(1): 228.     CrossRef
  • Tryptanthrin Down-Regulates Oncostatin M by Targeting GM-CSF-Mediated PI3K-AKT-NF-κB Axis
    Na-Ra Han, Hi-Joon Park, Seong-Gyu Ko, Phil-Dong Moon
    Nutrients.2024; 16(23): 4109.     CrossRef
  • 3,655 View
  • 329 Download
  • 2 Web of Science
  • 2 Crossref
Close layer
Letters to the Editor
IBD
Update on SARS-CoV-2 vaccination of patients with inflammatory bowel disease: what clinicians need to know
Yoo Jin Lee, Seong-Eun Kim, Yong Eun Park, Ji Young Chang, Hyun Joo Song, Duk Hwan Kim, Young Joo Yang, Byung Chang Kim, Jae Gon Lee, Hee Chan Yang, Seung-Jae Myung, Clinical Practice Guideline Committee of the Korean Association for the Study of Intestinal Diseases
Intest Res 2022;20(3):386-388.   Published online March 11, 2022
DOI: https://doi.org/10.5217/ir.2020.00172
PDFPubReaderePub
  • 3,829 View
  • 327 Download
Close layer

Intest Res : Intestinal Research
Close layer
TOP